Pediatric blood & cancer · 2007
Role of chemotherapy resistance genes in outcome of neuroblastoma.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
de Cremoux Patricia, Jourdan-Da-Silva Nathalie, Couturier Jérôme, Tran-Perennou Carine, Schleiermacher Gudrun, Fehlbaum Pascale, Doz François, Mosseri Véronique, Delattre Olivier, Klijanienko Jerzy, Vielh Philippe, Michon Jean
Аннотация
BACKGROUND: Neuroblastoma is a heterogeneous pediatric disease. Most patients with localized disease usually have a favorable prognosis, but patients with advanced disease have a poor prognosis despite combination chemotherapy. Treatment failure may be attributable to resistance to cytotoxic drugs.
PROCEDURE: Using quantitative RT-PCR, we investigated the clinical significance of the level of mRNA expression of multidrug resistance genes (MDR1, MRP1, MRP5, LRP) in a series of 29 advanced neuroblastoma samples.
RESULTS: At the end of induction chemotherapy, 48% of patients achieved a clinical complete response, 28% achieved a partial response or stable disease, and 24% presented progressive disease. MDR1 mRNA overexpression (i.e., mRNA level >2 copies of MDR1 gene) was observed in 74% of samples, and MRP1, MRP5, LRP overexpression was observed less frequently (30, 33, and 33% of samples, respectively). None of these parameters were predictive of response, relapse, or survival. However, clinical response to treatment was highly predictive of relapse-free survival and overall survival.
CONCLUSIONS: High expression of these multidrug resistance genes in advanced neuroblastoma is not the main parameter of response to cytotoxic drugs; clinical response to treatment remains the most important parameter in predicting the prognosis of patients with advanced neuroblastoma, until other relevant laboratory parameters have been identified.
PROCEDURE: Using quantitative RT-PCR, we investigated the clinical significance of the level of mRNA expression of multidrug resistance genes (MDR1, MRP1, MRP5, LRP) in a series of 29 advanced neuroblastoma samples.
RESULTS: At the end of induction chemotherapy, 48% of patients achieved a clinical complete response, 28% achieved a partial response or stable disease, and 24% presented progressive disease. MDR1 mRNA overexpression (i.e., mRNA level >2 copies of MDR1 gene) was observed in 74% of samples, and MRP1, MRP5, LRP overexpression was observed less frequently (30, 33, and 33% of samples, respectively). None of these parameters were predictive of response, relapse, or survival. However, clinical response to treatment was highly predictive of relapse-free survival and overall survival.
CONCLUSIONS: High expression of these multidrug resistance genes in advanced neuroblastoma is not the main parameter of response to cytotoxic drugs; clinical response to treatment remains the most important parameter in predicting the prognosis of patients with advanced neuroblastoma, until other relevant laboratory parameters have been identified.
Предметные рубрики MeSH
ATP Binding Cassette Transporter, Subfamily B, Member 1AdolescentAntineoplastic Combined Chemotherapy ProtocolsCarboplatinCell Line, TumorChildChild, PreschoolChromosome DeletionChromosomes, Human, Pair 1CisplatinComputer SystemsCyclophosphamideDisease-Free SurvivalDoxorubicinDrug Resistance, MultipleDrug Resistance, NeoplasmEtoposideFemaleGene Expression ProfilingGenes, MDRGenes, mycHumansInfantKaplan-Meier EstimateMaleATP-Binding Cassette, Sub-Family C ProteinsNeoplasm ProteinsNeuroblastomaPrecursor Cell Lymphoblastic Leukemia-LymphomaRNA, MessengerRNA, NeoplasmReverse Transcriptase Polymerase Chain ReactionS PhaseTreatment OutcomeVault Ribonucleoprotein ParticlesVincristineMajor Vault Protein